Clear Vision for Healthcare Investing
08.18.2014EISAI SUBMITS MARKETING APPROVAL APPLICATIONS FOR ANTICANCER
AGENT LENVATINIB SIMULTANEOUSLY IN EUROPE AND U.S.
08.11.2014Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia.
More News >
Copyright © 2014 Clarus Ventures, LLC - All Rights Reserved